| Senast Betalt | Daglig förändring |
|---|---|
| 68.2 |
| AKTIE | Valuta | Omsättning | % | +/- | Köp | Sälj | Högst | Lägst | Datum |
|---|---|---|---|---|---|---|---|---|---|
| Diamyd Medical B | SEK | 67.7 | 67.6 | 2020-09-25 |
| Namn | Värde |
|---|---|
| Antal Aktier | 66613573 |
| Börsvärde | 4543045678.6 |
| Genomsnittlig dagsomsät. | |
| VD | Ulf Hannelius |
| Styrelseordf. | Erik Nerpin |
| Namn | Värde |
|---|---|
| Volatitet 30 dagar | 106.30% |
| Volatitet 200 dagar | 101.02% |
| Utdelning Senaste årsredovisningen |
|
| Direktavkastning |
Diamyd Medical is a diabetes company headquartered in Stockholm, Sweden. The Company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trials, leading to one of Sweden’s largest biotech agreements ever.
| 2019 | 2018 | 2017 | |
|---|---|---|---|
| Nettoomsättning | 1.57 | 0.73 | 0.92 |
| Bruttoreslutat | -20.72 | -28.30 | -11.84 |
| Ebitda | -36.43 | -43.91 | -25.41 |
| Ebit | -36.57 | -44.04 | -25.52 |
| Resultat före skatt | -36.61 | -43.95 | -25.56 |
| Nettoresultat | -36.61 | -43.95 | -25.56 |
| EPS (SEK) | -0.53 | -0.78 | -0.76 |
| DPS (SEK) |
| 2019 | 2018 | 2017 | |
|---|---|---|---|
| Omsättningstillväxt Å/Å | 115.98% | -21.26% | 21.8% |
| Bruttomarginal | -1321.56% | -3897.93% | -3069.31% |
| EBITDA-marginal | -2323.28% | -6047.52% | -4761.93% |
| EBIT-marginal | -2332.21% | -6065.56% | -4776.14% |
| Nettomarginal | -2334.82% | -6054.13% | -4767.14% |
| 2019 | 2018 | 2017 | |
|---|---|---|---|
| Likvida medel | 36.70 | 14.08 | 55.69 |
| S:a omsättningstillgångar | 61.88 | 47.19 | 91.07 |
| S:a tillgångar | 74.20 | 54.98 | 98.65 |
| Eget kapital | 62.78 | 43.01 | 86.67 |
| S:a skulder | 11.42 | 11.97 | 11.98 |
| Nettoskuld | -55.94 | -43.34 | -55.69 |
